Skip to main content
TipRanks
Go Ultimate75% OFF

JOSEPH FRATTAROLI Insider Profile

4 Followers

JOSEPH FRATTAROLI, Cheif Financial Officer at Inhibikase Therapeutics, holds 48.09K shares in Inhibikase Therapeutics (Ticker: IKT). Most recently, JOSEPH FRATTAROLI Bought 3,948 shares of Inhibikase Therapeutics on May 23, 2022 for an estimated value of $2.53K.

JOSEPH FRATTAROLI's Trading History

IKT
Inhibikase Therapeutics
May 23, 2022Cheif Financial OfficerInformative Buy2.53K$73.10K
IKT
Insider Shares: 48.09K (0.17%)
DateTransactionAmountNo. of SharesPrice per ShareProfitLink to Report
May 23, 2022Informative Buy$2.53K3,948$0.64-17.10%
Dec 29, 2020Informative Buy$441.43K44,143$10.00-81.80%

You May Also Like

JOSEPH FRATTAROLI insider profile FAQ

What is the percentage of profitable transactions made by JOSEPH FRATTAROLI?
The percentage of profitable transactions made by JOSEPH FRATTAROLI is 0%.
What is the average return per transaction made by JOSEPH FRATTAROLI?
The average return per transaction made by JOSEPH FRATTAROLI is -49.40%.
What stocks does JOSEPH FRATTAROLI hold?
JOSEPH FRATTAROLI holds: IKT stocks.
What was JOSEPH FRATTAROLI’s latest transaction?
JOSEPH FRATTAROLI’s latest transaction was an Informative Buy of $2.53K.
What was JOSEPH FRATTAROLI's most profitable transaction?
JOSEPH FRATTAROLI’s most profitable transaction was an Informative Buy of IKT stock on May 23, 2022. The return on the trade was -17.10%.
What is JOSEPH FRATTAROLI's role in Inhibikase Therapeutics?
JOSEPH FRATTAROLI's role in Inhibikase Therapeutics is Cheif Financial Officer.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.